Our deep immunological and infectious disease expertise, coupled with our flexible funding structure, has allowed us to respond quickly to emerging infectious diseases throughout the years.

Ragon scientists have been able to respond swiftly to new diseases from COVID-19 to Zika, thanks in part to our incredible, donor-supported flexible funding model.

We work towards understanding, preventing, and treating these diseases while identifying and studying viruses which could potentially turn pathogenic in the future.

Our labs have helped support vaccine development for COVID-19 and Zika, work to understand high-risk viral classes such as flaviviruses, and analyze the immune response to novel pathogenic viruses.